Key Highlights

  • Modular Medical secured FDA 510(k) clearance for software updates to its Pivot tubeless insulin pump.
  • The updates enhance user-interface features and bolus delivery options.
  • The company anticipates a limited commercial rollout across five domestic territories starting in October 2026.
  • The update focuses on technological refinements rather than new clinical data or financing.

Modular Medical, Inc. (NASDAQ: MODD) secured FDA 510(k) clearance for software updates to its Pivot tubeless insulin pump, a move that enhances user-interface features and bolus delivery options.

What Happened

The company anticipates a limited commercial rollout across five domestic territories starting in October 2026, though the current update focuses on technological refinements rather than new clinical data or financing rounds.

Market Reaction

The disclosed information does not include stock price or trading data for Modular Medical following the FDA clearance.

Outlook

The planned October 2026 limited commercial rollout across five domestic territories represents the next major milestone for the updated Pivot insulin pump.